Factsheet and Information Brochure
Factsheet
Target Market
Costs and charges
Fund rules (190 kB)
Prospectus (1181 kB)
Periodic reports
Sustainability SFDR (875 kB)
Annual review (PF) (2827 kB)
Semi-annual report (1799 kB)
Marketing material
Sustainability profile
Brief fund information
Summary SFDR (164 kB)
Handelsbanken Hälsovård Tema (A10 NOK)
Legal name: Handelsbanken Hälsovård Tema (A10 NOK)
Equity Fund Registered in Sweden (UCITS)
Bid
About risk
Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. Summary of investors' rights.
The fund is actively managed and invests globally in equities issued by companies within the healthcare sector. As a result, the fund has a currency exposure to these markets. The healthcare sector refers to the pharmaceutical, medical technology, biotech, service and other healthcare-related branches.
The thematic investment strategy provides for investments that occur in a limited area in which development is deemed to result in a structural change to the economy and society. This change provides favorable conditions for companies active within the area to create profitable growth over time.
The fund is reported as an Article 9 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
The thematic investment strategy provides for investments that occur in a limited area in which development is deemed to result in a structural change to the economy and society. This change provides favorable conditions for companies active within the area to create profitable growth over time.
The fund is reported as an Article 9 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
Fund manager
Christopher Sundman Experience in the fund industry 1987. Portfolio Manager since 1 August 2022.
|
|
||
|---|---|---|---|
|
The risk indicator provides guidance on the risk level for this product relative to other financial products. It shows the likelihood that the product will decrease in value due to market performance. Risk level 1 represents a low risk and risk level 7 is a high risk.
|
|
30.04.2024
|
||
|---|---|---|---|
|
The rating shows which funds have historically posted the strongest performance in relation to risk. Ratings are denoted by a scale of one to five stars, with five as the highest rating. A fund must have a performance history of at least three years to receive a rating.
Read more about the fund's rating |
|
|
||
|---|---|---|---|
|
The fund has sustainable investments as its objective. Accordingly, the fund invests in companies with products and services that are considered as contributing positively to the direct fulfillment of one or several of the targets in Agenda 2030. Refer to the fund's prospectus for additional information. The fund is reported as an Article 9 fund pursuant to EU regulation on sustainability-related disclosures in the financial services sector (SFDR). Read more |
|
29.02.2024
|
|||
|---|---|---|---|
|
The sustainability rating is developed by the fund information company Morningstar. The rating measures how well the fund's investee companies manage sustainability risks relative to other funds within the same global Morningstar category. If the fund has invested in government bonds issued by sovereign states, the respective country's sustainability risk is included in the calculation. The analyzed funds can receive a sustainability rating between 1 and 5 globes, with 5 as the highest rating. The fund complies with the UN Principles for Responsible Investments. |
Graph
Performance
| Rate 08.05.2024 | 1 week | 1 month | 3 months | 2024 | 1 year | 5 years | 10 years |
|---|---|---|---|---|---|---|---|
| 495.56 NOK | -0.32% | 3.34% | 6.95% | 17.07% | 16.64% | - | - |
Portfolio 26.04.2024
The year began strongly for the fund, which rose just over 16% in SEK during Q1.
Eli Lilly, Novo Nordisk and Zealand Pharma continued as the strongest contributors within the diabetes/obesity area. In conjunction with its capital market day at the beginning of March, Novo Nordisk presented positive data on oral amycretin, an obesity drug that results in a weight loss of 13% after just 12 weeks and has very few side effects. Zealand Pharma also presented very strong Phase 2 data on MASH (liver fats), in addition to weight loss with its Survodutide drug and the share rose 30%.
On the negative side was Evotec, whose share price fell when the company’s CEO resigned unexpectedly due to unreported trades in the company’s shares. Our assessment is that the company’s operations and positive outlooks have not been affected and that this is more of a short-term uncertainty. Bioarctic also declined on the back of uncertainty about the target of treating 10,000 patients with Leqembi by the end of Q1. However, our outlook is positive, although it may take longer due to a limited capacity for diagnosis.
In general, we are more positive to the sector this year given that interest rates are stabilizing and access to capital for early biotech and medical technology companies is beginning to return. New holdings in the fund include the medical technology company Shockwave Medical, which uses electrical shockwaves to remove calcification in patients with cardiovascular diseases, as well as Immunome, which works with early research within oncology that focuses on ADC drugs.
Portfolio distribution 30.04.2024
Geographic breakdown 30.04.2024
